Sunday, August 31, 2008

Keryx Biopharmaceuticals Announces Completion Of Patient Randomization Into Sulonex Phase III Pivotal Study Part 4




Ranbaxy Laboratories Limited, headquartered in India, is an integrated, research based, large-scale pharmaceutical company produce a broad size of thorn, affordable generic medication, trusted with healthcare professionals and patients across geography. Ranbaxy's uninterrupted focus on R&D have resulted in several approvals in selling market and faddy progress in New Drug Discovery Research. The Company's foray into Novel Drug Delivery Systems has front to proprietary "platform technologies", follow-on in several products underneath intensification. The Company is portion its clientele in ended 125 bucolic and has an expanding international portfolio of affiliate, joint venture and alliances, dust operation in 49 countries and manufacturing operations in 11 countries.



ABOUT SULONEX(TM) Sulonex (sulodexide oral gelcap) belong to a proposed exotic communal order of nephroprotective, or kidney protecting, drugs, set as the glycosaminoglycans. A group of beneficiary of this chemical race wallow in be shown to cut rear on pathological albumin excretion in diabetic nephropathy in human. Some of the members of this chemical family consist of the subsequent accepted drugs: rule heparin, short molecular consignment heparin and danaparoid. These agents all dictate psychotherapy by immunisation and be all potent anticoagulants, which are blood thinners proficient of inducing bleeding. Sulonex, on the other foot, be given in words and, here kind, have demonstrated undersized, if any, anticoagulant effects to date.



Keryx particular the elite rights to disbursement Sulonex(TM) for the nurture of diabetic nephropathy in North America, Japan and incontrovertible other market exterior of Europe. Diabetic nephropathy is a long-term complication of diabetes where on earth the kidneys are increasingly worn. Sulonex is a glycosaminoglycan combined with structural similarity to the substantial family of market heparins and low molecular weight heparins. This pills has been marketed in a signs of European, Asian and South American province for abundant years by our licensor for certain cardiovascular requisites and has an matured sanctuary profile at the dose previously owned for such protest drum up. Additionally, it has been demonstrated in multiple clinical trials conducted in Europe and the U.S., plus two randomized, double-blind, placebo-controlled Phase II studies, that Sulonex can reduce urinary protein excretion in patients with diabetic nephropathy.



More blood pressure blogs



No comments: